Vanada Pharmaceuticals has announced that its drug, iloperidone, has been accepted for U.S. Food and Drug Administration New Drug Application (NDA). Iloperidone is an investigational atypical antipsychotic for the treatment of schizophrenia.
In other FDA news, Watson Pharmaceuticals Inc announced that it received final approval on its ANDA for Oxycodone Hydrochloride and Ibuprofen tablets in the 5/400 mg strengths. Waston's product is the generic equivalent of Forest Laboratories Inc.'s Combunox which is used for the short term (no more than 7 days) treatment of acute, moderate to severe pain.
The FDA has accepted filing of a NDA for Schering-Plough's asenapine, a fast-dissolving, sub-lingual tablet for schizophrenia and acute mania associated with Bipolar I Disorder. To date clinical trials have consisted of over 3000 patients with schizophrenia or bi-polar mania.
[Source: PRNewsWire]
» Schering-Plough from PharmaGazette
Last but not least is Schering-Plough who falls 15th on the r&d budget list ($1.65 bn EUR) and 16th in over all sales for 2006. After a number of bad years Schering has put itself back in the running with... [Read More]
Tracked on: December 14, 2007 11:09 AM | Permalink to Trackback